Approximately 3 in 1000 women will receive a diagnosis of vulvar cancer at some point in
their lives. More than one in three will be diagnosed at an advanced stage, with reduced …

Further clinical research should focus on deciphering the molecular mechanisms of tumor
development further. Detailed understanding of the molecular landscape will help to find …

Vulva and vaginal cancers are rare tumors of the gynecologic tract accounting for only 5–8%
of all gynecologic malignancies in the US. In 2009, there were 3580 women diagnosed with …

When we proposed the topics for this Special Issue, our first thought was to integrate the
results from the latest original research to practical reviews focusing on key questions. Both …

Vulvar cancer is an uncommon gynecological malignancy primarily affecting
postmenopausal women. There is no specific screening and the most effective strategy to …

The treatment of patients with vulvar cancer remains challenging for gynecologic
oncologists. Up to 30% of the cases are diagnosed in a clinical condition of irresectability …

Introduction Due to scant literature and the absence of high-level evidence, the treatment of
vulvar cancer is even more challenging in countries facing limited resources, where direct …

Simple Summary Vulvar cancer is a rare gynaecological malignancy that has an increasing
incidence, particularly in younger women. Early vulvar cancer can be treated and cured with …

Vulvar carcinoma is an uncommon tumor that is seen most often in older women. Subtle
symptoms such as pruritus should prompt examination and targeted biopsy in all women as …

Vulvar cancer (VC) accounts for 5% of all gynecologic cancer and the most common
histological type is squamous cell carcinoma (up to 90%)[1]. The median age of VC is over …